Skip to main content
OpenTrials
Completed

NCT Number: NCT06269302

Comparison of the Effect of Warfarin and Direct Oral Anticoagulants

In this study, it was aimed to compare the frequency of new oral anticoagulants and warfarin usage, and to reveal the rates of recurrent upper gastrointestinal bleeding among patients who applied to our hospital with upper gastrointestinal bleeding

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Anticoagulants and Bleeding Disorders Cardiovascular Diseases Digestive System Diseases Gastrointestinal Diseases Gastrointestinal Hemorrhage Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhage Hemorrhagic Disorders Hemostatic Disorders Pathologic Processes Pathological Conditions, Signs and Symptoms Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Samsun Education and Research Hospital

Samsun, İlkadım, Turkey (Türkiye)

About this study

The data of all patients who applied to Samsun Training and Research Hospital Internal Medicine with a diagnosis of upper gastrointestinal bleeding and hospitalized by Internal Medicine and Gastroenterology clinics or who underwent outpatient endoscopy between 01.01.2021 and 31.12.2021 were included. The patients' data were analyzed from the patient files and hospital automation system retrospectively. Patients who had recurrent upper GI bleeding were detected by controlling them over the hospital software system and by reaching each patient again. The frequency of the new generation oral anticoagulants usage in patients with re-bleeding was determined, and data such as re-bleeding rate, length of hospital stay, need for transfusion, and mortality were analyzed in the groups who did not use this drug and those who used it. The patient demographics were also compared between the groups who were using the new generation oral anticoagulants, acetylsalicylic acid or warfarin.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >18 years old
  • Upper gastrointestinal bleeding
  • 12 months follow-up

Exclusion criteria

  • Age <18 years old
  • Lower gastrointestinal bleeding
  • Esophageal variceal bleeding

Treatment and study plan

Primary outcomes

  1. Change in the incidence of recurrent bleeding

    Time frame: 12 months

    Increase or decrease in the incidence of recurrent bleeding

Sponsors and collaborators

Lead sponsor

Samsun Education and Research Hospital

Other

Registry information

Official study title

Comparison of the Effect of Warfarin and Direct Oral Anticoagulants on Upper Gastrointestinal System Bleeding

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Feb 21, 2024
Registry last updated
Feb 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.